Table 8.6a

Immunosuppression Use for Induction, 1995 to 2004

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 919 861 853 972 943 914 891 905 870 880
With Immunosuppression Info 918 861 850 969 937 906 887 899 860 842
Induction Drugs 27.0% 1.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 7.1% 32.1% 36.2% 13.4% 6.2% 3.0% 2.6% 2.8% 1.9% 2.6%
OKT3 59.9% 51.9% 42.5% 27.5% 15.3% 8.2% 3.5% 1.1% 0.3% 0.8%
Thymoglobulin 0.0% 0.2% 0.1% 0.4% 8.4% 22.7% 28.7% 39.2% 48.7% 44.3%
Zenapax 0.3% 0.1% 0.4% 20.4% 27.0% 21.9% 20.0% 16.4% 8.3% 5.1%
Simulect 0.3% 0.1% 0.4% 8.4% 17.1% 26.9% 31.0% 26.3% 16.0% 12.4%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7.8% 18.9%
No Induction Drugs Recorded 15.0% 18.5% 26.2% 35.2% 34.2% 27.2% 24.5% 23.6% 20.8% 20.5%


Source: OPTN/SRTR Data as of May 2, 2005.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.